Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.5910
-0.0444-6.99%
Volume:253.23K
Turnover:149.20K
Market Cap:70.90M
PE:-0.41
High:0.6097
Open:0.6048
Low:0.5700
Close:0.6354
Loading ...

What's Going On With Invivyd Stock On Monday?

Benzinga
·
21 Apr

BRIEF-Invivyd Announces $30M Non-Dilutive Loan Facility With Silicon Valley Bank

Reuters
·
21 Apr

Invivyd Announces $30M Non-Dilutive Loan Facility With Silicon Valley Bank

THOMSON REUTERS
·
21 Apr

Press Release: Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Dow Jones
·
21 Apr

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to Its Board of Directors

THOMSON REUTERS
·
27 Mar

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

GlobeNewswire
·
27 Mar

Invivyd Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Mar

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Mar

Invivyd FY 2024 GAAP EPS $(1.43) Beats $(1.48) Estimate, Sales $25.38M Beat $25.15M Estimate

Benzinga
·
20 Mar

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

THOMSON REUTERS
·
20 Mar

Invivyd Inc - Vyd2311 Commercial Manufacturing Completed, Minimal Expenses Expected in 2025

THOMSON REUTERS
·
20 Mar

Invivyd Inc: Continues to Target Profitability by End of 1H 2025

THOMSON REUTERS
·
20 Mar

Invivyd Inc - Q4 2024 Pemgarda Revenue $13.8 Mln, up 48% From Q3 2024

THOMSON REUTERS
·
20 Mar

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
05 Mar

Invivyd Inc: Pemivibart Antiviral Activity Remains Within Range of Expected Assay Variability Since Omicron Ba.2

THOMSON REUTERS
·
05 Mar

Invivyd Inc - Vyd2311 Shows Clinically Meaningful Neutralization Against Lp.8.1

THOMSON REUTERS
·
05 Mar

Invivyd Announces Continued Neutralizing Activity of Pemgarda™ (Pemivibart) Against Currently Dominant Sars-Cov-2 Variant Lp.8.1

THOMSON REUTERS
·
05 Mar

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

GlobeNewswire
·
05 Mar

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Simply Wall St.
·
05 Mar

Invivyd (NasdaqGM:IVVD) Surges 198% After Positive Results From VYD2311 COVID-19 Trial

Simply Wall St.
·
28 Feb